| scholarly article | Q13442814 |
| P50 | author | Raymond Chuen-Chung Chang | Q41932816 |
| P2093 | author name string | Linda Zhang | |
| Henry Ka-Fung Mak | |||
| Leung-Wing Chu | |||
| P2860 | cites work | Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 |
| Cholinesterase inhibitors for Alzheimer's disease | Q22252975 | ||
| Long-term course and effectiveness of combination therapy in Alzheimer disease | Q24642161 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment | Q24645655 | ||
| 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment | Q24648319 | ||
| Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment | Q24804621 | ||
| Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1 | Q28118975 | ||
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Skeletal and CNS defects in Presenilin-1-deficient mice | Q28238795 | ||
| Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice | Q28300764 | ||
| Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm | Q28585594 | ||
| Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein | Q28592893 | ||
| beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity | Q28593175 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria | Q29614408 | ||
| Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains | Q29616293 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Amyloid deposition as the central event in the aetiology of Alzheimer's disease | Q29619450 | ||
| Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial | Q44735780 | ||
| Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor | Q44777442 | ||
| Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies | Q44820313 | ||
| Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile | Q44906525 | ||
| Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease | Q44940013 | ||
| Dynamics of gray matter loss in Alzheimer's disease. | Q46191030 | ||
| Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease | Q46388486 | ||
| PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. | Q46404881 | ||
| Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy | Q46528864 | ||
| Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging | Q46764922 | ||
| Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. | Q47230871 | ||
| Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele | Q47298772 | ||
| Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes | Q47583031 | ||
| A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease | Q47583762 | ||
| Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease | Q47671587 | ||
| Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition | Q47844222 | ||
| Diffusion-weighted and magnetization transfer imaging of the corpus callosum in Alzheimer's disease | Q48104476 | ||
| Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice | Q48127495 | ||
| PET imaging of amyloid deposition in patients with mild cognitive impairment | Q48169392 | ||
| Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials | Q48171083 | ||
| Primate learning tasks reveal strong impairments in patients with presenile or senile dementia of the Alzheimer type | Q48198165 | ||
| Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging | Q48453447 | ||
| Imaging markers of mild cognitive impairment: multivariate analysis of CBF SPECT. | Q48477449 | ||
| Quantitative assessment of cerebral hemodynamic parameters by QUASAR arterial spin labeling in Alzheimer's disease and cognitively normal Elderly adults at 3-tesla | Q48567726 | ||
| Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins | Q48601563 | ||
| Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model | Q48635943 | ||
| Simultaneous measurement of arterial transit time, arterial blood volume, and cerebral blood flow using arterial spin-labeling in patients with Alzheimer disease | Q48675651 | ||
| Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510) | Q43594370 | ||
| Memantine in moderate-to-severe Alzheimer's disease | Q44388745 | ||
| Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? | Q44411562 | ||
| Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment | Q44571913 | ||
| Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity | Q44583358 | ||
| Apolipoprotein E e4 allele in the normal elderly: neuropsychologic and brain MRI correlates | Q48868567 | ||
| Neuronal activity and early neurofibrillary tangles in Alzheimer's disease | Q48935126 | ||
| A new experimental approach and signal processing scheme for the detection and quantitation of ³¹P brain neurochemicals from in vivo MRS studies using dual tuned (¹H/³¹P) head coil | Q48960744 | ||
| Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. | Q49028511 | ||
| Parkinson disease: diagnostic utility of diffusion kurtosis imaging | Q49031391 | ||
| Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. | Q50907793 | ||
| The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. | Q51855473 | ||
| Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. | Q51891117 | ||
| Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. | Q51919586 | ||
| Model-free arterial spin labeling quantification approach for perfusion MRI. | Q51955793 | ||
| Potential role of diffusion tensor MRI in the differential diagnosis of mild cognitive impairment and Alzheimer's disease. | Q51965306 | ||
| Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. | Q51978363 | ||
| Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. | Q52052697 | ||
| Brain iron and ferritin in Parkinson's and Alzheimer's diseases. | Q53184175 | ||
| Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. | Q53212464 | ||
| Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. | Q53235144 | ||
| Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. | Q53338394 | ||
| Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. | Q53341374 | ||
| Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. | Q53350823 | ||
| Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. | Q53364124 | ||
| Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. | Q53454566 | ||
| Hopes remain for an Alzheimer's vaccine | Q59068383 | ||
| Dosing in phase II trial of Alzheimer's vaccine suspended | Q73632329 | ||
| Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia | Q73924763 | ||
| Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study | Q74309189 | ||
| Single photon emission computed tomography perfusion differences in mild cognitive impairment | Q36226953 | ||
| Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study | Q36316973 | ||
| Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele | Q36318674 | ||
| 31P nuclear magnetic resonance (NMR) spectroscopy of brain in aging and Alzheimer's disease. | Q36447528 | ||
| Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy | Q36707869 | ||
| Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology | Q36724967 | ||
| The projected effect of risk factor reduction on Alzheimer's disease prevalence | Q36825862 | ||
| Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging | Q36871035 | ||
| Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias | Q36990181 | ||
| Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. | Q37041524 | ||
| The value of incomplete mouse models of Alzheimer's disease | Q37083271 | ||
| Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease | Q37118356 | ||
| MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice | Q37295234 | ||
| PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. | Q37351230 | ||
| Animal models of Alzheimer's disease: therapeutic implications. | Q37354734 | ||
| Modeling Tauopathy in the fruit fly Drosophila melanogaster | Q37354741 | ||
| The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. | Q37354744 | ||
| The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. | Q37354760 | ||
| Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders | Q37354764 | ||
| Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease | Q37398634 | ||
| Donepezil in severe Alzheimer's disease | Q37402181 | ||
| Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study | Q37407266 | ||
| Effects of injected Alzheimer beta-amyloid cores in rat brain. | Q37596908 | ||
| Vascular risk factor detection and control may prevent Alzheimer's disease | Q37729423 | ||
| Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease | Q37866098 | ||
| Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents | Q38394981 | ||
| Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias | Q38500630 | ||
| Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease | Q39873732 | ||
| In vivo measurement of plaque burden in a mouse model of Alzheimer's disease | Q40171019 | ||
| The gene defects responsible for familial Alzheimer's disease | Q41288332 | ||
| Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease | Q41399691 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Alzheimer's disease through the eye of a mouse. Acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize | Q42165184 | ||
| Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits | Q42521273 | ||
| In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent | Q42556930 | ||
| Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study | Q43570563 | ||
| Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion | Q30810310 | ||
| Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics | Q30908064 | ||
| Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience | Q30983673 | ||
| The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease | Q31030916 | ||
| Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics | Q31047131 | ||
| Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research | Q31093609 | ||
| White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques | Q31110382 | ||
| Non-mono-exponential attenuation of water and N-acetyl aspartate signals due to diffusion in brain tissue | Q32071895 | ||
| Proteomic analysis for protein carbonyl as an indicator of oxidative damage in senescence-accelerated mice | Q33260812 | ||
| A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease | Q33292093 | ||
| Alzheimer's disease: clinical trials and drug development | Q33349401 | ||
| Age-related non-Gaussian diffusion patterns in the prefrontal brain | Q33386359 | ||
| Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications | Q33391815 | ||
| Transgenic animals relevant to Alzheimer's disease | Q33588638 | ||
| MR diffusion kurtosis imaging for neural tissue characterization. | Q33630700 | ||
| Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. | Q33697980 | ||
| SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele | Q33735332 | ||
| Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy | Q33920295 | ||
| Aβ oligomers inhibit synapse remodelling necessary for memory consolidation | Q33936929 | ||
| Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis | Q33950420 | ||
| Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo | Q34063772 | ||
| Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes | Q34452028 | ||
| Alzheimer disease as a vascular disorder: nosological evidence | Q34589057 | ||
| Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease | Q34589414 | ||
| Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain | Q34725521 | ||
| Amyloid-beta: a vascular sealant that protects against hemorrhage? | Q34976258 | ||
| (99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease | Q35010269 | ||
| Alzheimer's disease: how does it start? | Q35039914 | ||
| Dying for a cause: invertebrate genetics takes on human neurodegeneration | Q35074847 | ||
| White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging | Q35467884 | ||
| Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders | Q35573431 | ||
| Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease | Q35607811 | ||
| Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. | Q35609244 | ||
| Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates | Q35876784 | ||
| P433 | issue | 3 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| neuroimaging | Q551875 | ||
| P304 | page(s) | 386-404 | |
| P577 | publication date | 2012-07-10 | |
| P1433 | published in | American journal of nuclear medicine and molecular imaging | Q27723780 |
| P1476 | title | Current neuroimaging techniques in Alzheimer's disease and applications in animal models | |
| P478 | volume | 2 |
| Q34571189 | A review of neuroimaging biomarkers of Alzheimer's disease |
| Q37590895 | Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease |
| Q28537832 | Hemodynamic and neuropathological analysis in rats with aluminum trichloride-induced Alzheimer's disease |
| Q26765945 | Insight into the Molecular Imaging of Alzheimer's Disease |
| Q37110373 | Molecular imaging strategies for in vivo tracking of microRNAs: a comprehensive review |
| Q38112726 | Multimodality imaging of RNA interference |
| Q35946092 | Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease |
| Q38430889 | Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features |
| Q28388580 | Pharmacokinetic issues of imaging with nanoparticles: focusing on carbon nanotubes and quantum dots |
| Q36746567 | Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121. |
| Q37337213 | Quantum dot-based nanoprobes for in vivo targeted imaging |
| Q37649861 | Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics |
Search more.